Results 111 to 120 of about 2,211,903 (315)
Clinical trials on trial [PDF]
It has been 3 years since I wrote an editorial on the topic of uncertainty around new cancer treatments (issue 4 of volume 2009). Has this field progressed in 3 years? I think the answer is both yes and no. Yes because we now have a clearer picture of why cancer drugs can sometimes act differently (usually worse) in real life situations than they seem ...
openaire +2 more sources
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley +1 more source
JKN2306 is a novel, highly selective Nav1.8 inhibitor under development for the treatment of acute pain. This first‐in‐human study aimed to evaluate its safety, tolerability, pharmacokinetics, and food effect (FE).
Ying Yang +14 more
doaj +1 more source
Conventional cosmetic human studies rely on pre–post mean comparisons, which have limitations in explaining where and how facial skin changes occur. This pilot single-arm study proposed a privacy-preserving three-dimensional (3D) facial mesh mapping ...
Youngrin Kwag +6 more
doaj +1 more source
In this study, we found that human cervical‐derived adipocytes maintain intracellular iron level by regulating the expression of iron transport‐related proteins during adrenergic stimulation. Melanotransferrin is predicted to interact with transferrin receptor 1 based on in silico analysis.
Rahaf Alrifai +9 more
wiley +1 more source
Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley +1 more source
Qiulin Xiang,1 Yi Yang,1 Guoxing Li,1 Song Chen,1,2 Yingying Yang,1,3 Ling Liu,4 Xian Yu1 1Department of Phase I Clinical Trial Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Pharmacy ...
Xiang Q +6 more
doaj
Design considerations in a clinical trial of a cognitive behavioural intervention for the management of low back pain in primary care : Back Skills Training Trial [PDF]
Background Low back pain (LBP) is a major public health problem. Risk factors for the development and persistence of LBP include physical and psychological factors. However, most research activity has focused on physical solutions including manipulation,
Hansen, Zara +41 more
core +1 more source
Biomolecular condensates formed by fused in sarcoma (FUS) are dissolved by high ATP concentrations yet persist in cells. Using a reconstituted system, we demonstrate that valosin‐containing protein (VCP), an AAA+ ATPase, counteracts ATP‐driven dissolution of FUS condensates through its D2 ATPase activity.
Hitomi Kimura +2 more
wiley +1 more source
Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz +11 more
wiley +1 more source

